4-[[[4-(4-氯苯氧基)苯基]磺酰基]甲基]四氢-N-羟基-2H-吡喃-4-甲酰胺
| 中文名称 | 4-[[[4-(4-氯苯氧基)苯基]磺酰基]甲基]四氢-N-羟基-2H-吡喃-4-甲酰胺 |
|---|---|
| 中文同义词 | 4-[[[4-(4-氯苯氧基)苯基]磺酰基]甲基]四氢-N-羟基-2H-吡喃-4-甲酰胺;MMP抑制剂(CTS-1027) |
| 英文名称 | CTS-1027 |
| 英文同义词 | CTS-1027;2H-Pyran-4-carboxaMide, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]Methyl]tetrahydro-N-hydroxy-;Ro 1130830;Ro1130830;Ro-1130830;RS 130830;RS130830;RS-130830 |
| CAS号 | 193022-04-7 |
| 分子式 | C19H20ClNO6S |
| 分子量 | 425.88 |
| EINECS号 | |
| 相关类别 | 代谢;细胞生物学试剂 |
| Mol文件 | 193022-04-7.mol |
| 结构式 | ![4-[[[4-(4-氯苯氧基)苯基]磺酰基]甲基]四氢-N-羟基-2H-吡喃-4-甲酰胺 结构式](CAS/20150408/GIF/193022-04-7.gif) |
4-[[[4-(4-氯苯氧基)苯基]磺酰基]甲基]四氢-N-羟基-2H-吡喃-4-甲酰胺 性质
| 密度 | 1.388±0.06 g/cm3(Predicted) |
|---|---|
| 储存条件 | Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 酸度系数(pKa) | 9.27±0.23(Predicted) |
CTS-1027 是一种有效的 MMP 抑制剂，能够作用于 MMP2 和 MMP13，IC50 值分别为 0.3 nM 和 0.5 nM。
IC50: 0.2 nM (MMP2), 0.5 nM (MMP13), 0.7 nM (MMP12), 0.9 nM (MMP8), 9.5 nM (MMP3), 15 nM (MMP14)
CTS-1027 significantly reduces the hepatocyte apoptosis, features of cholestatic liver injury, amd markers of hepatic fibrogenesis in the BDL mouse. CTS-1027 improves overall animal survival following 14 days of BDL in mice. In male animals treated for 8 weeks the terminal plasma concentration of RS-130830 is 311±45 nM. Treatment of male mice with RS-130830 for 8 weeks causes an 89% increase in plasma triglyceride concentration, but there is no corresponding effect in female mice treated for 12 weeks. The plaque lipid content of animals receiving RS-130830 is increased by 81% at 12 weeks, and increased by 41% at 16 weeks.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-10398 | CTS-1027 | 1 mg | 744元 | |
| 2024/01/25 | HY-10398 | 4-[[[4-(4-氯苯氧基)苯基]磺酰基]甲基]四氢-N-羟基-2H-吡喃-4-甲酰胺 CTS-1027 | 193022-04-7 | 5mg | 1500元 |